Efficacy and safety of galantamine (reminyl) in the treatment of dementia in patients with Parkinson's disease (open-label controlled trial)

Zhurnal Nevrologii i Psihiatrii imeni S.S. Korsakova

Volumn 107, Issue 12, 2007, Pages 25-33

  Litvinenko, I V ^a   Odinak, M M ^a   Mogilnaya, V I ^a   Emelin, A Yu ^a  

^a NONE

Author keywords

Dementia; Galantamine; Parkinson's disease

Indexed keywords

EID: 38949177020     PISSN: 19977298     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Russian source
2. Russian source
3. Russian source
4. Russian source
5. Aarsland D., Larsen J.P., Cumming J.L. et al. Prevalence and clinical correlates of psychotic symptoms in Parkinson's disease. Arch Neurol 1999; 56: 3: 595-601.
6. Aarsland D., Andersen K., Larsen J. P. et al. Risk of dementia in Parkinson's Disease: A community-based prospective study. Neurology 2001; 56: 6: 730-736.
7. Aarsland D., Hutchinson M., Larsen J.P. Cognitive, psychiatric and motor response to galantamine in Parkinson's disease with dementia. Int J Geriat Psychiat 2003; 18: 10: 937-941.
8. Bollard C., Piggott M., Johnson M. Delusions associated with elevated muscarinic binding in dementia with Lewy bodies. Ann Neurol 2000; 48: 6: 868-876.
9. Beach S.R., Schulz R. Caregiving as a risk factor for mortality: the Caregiver Health Effects Study. JAMA 1999; 282: 23: 2215-2219.
10. Bohnen N.I., Kaufer D.I., Ivanco L.S. et al. Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study. Arch Neurol 2003; 60: 12: 1745-1748.
11. Bohnen N.I., Kaufer D.I., Hendrickson R. et al. Cognitive correlates of cortical cholinergic denervation in Parkinson's disease and parkinsonian dementia. J Neurol 2005; 253: 2: 242-247.
12. Boyd J.L., Cruickshank C.A., Kenn C. W. et al. Cognitive impairment and dementia in Parkinson's disease: a controlled study. Psychol Med 1991; 21: 3: 911-921.
13. Bullock R., Cameron A. Rivastigmine for the treatment of dementia and visual hallucinations associated with Parkinson's disease: a case series. Curr Med Res Opin 2002; 18: 5: 258-264.
14. Catalan-Alonso M.J., Del Val J. Dopaminomimetic psychosis in Parkinson's disease: first symptom of early dementia? Rev Neurol 2001; 32: 11: 1085-1087.
15. Cummings J.L., Mega M., Gray K. et al. The Neuropsychiatrie Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994; 44: 12: 2308-2314.
16. Da Cunha C., Angelucci M.E., Conteras N. S. et al. The lesion of the rat substantia nigra pars compacta dopaminergic neurons as a model for Parkinson's disease memory disabilities. Cell Mol Neurobiol 2002; 22: 3: 227-237.
17. Duran Ferreras E., Chacon J., Duran Quintana J.A. The role of olanzapine in Parkinsonian dopaminergic psychosis. Rev Neurol 2002; 35: 7: 691-696.
18. Edwards K.R., Hershey L., Wray L. Efficacy and safety of galantamine in patients with dementia with Lewy bodies: a 12-week interim analysis. Dement Geriat Cogn Disord 2004; 17: Supll 1: 40-48.
19. Ernst R.L., Hay J. W. The US economic and social costs of Alzheimer's disease revisited. Am J Public Health 1994; 84: 8: 1261-1264.
20. Fabbrini G., Barbanti P., Aurilia C. et al. Donepezil in the treatment of hallucinations and delusions in Parkinson's disease. Neurol Sci 2002; 23: 1: 41-43.
21. Fenelon G., Mahieux F., Huon R. et al. Hallucinations in Parkinson's disease: Prevalence, phenomenology and risk factors. Brain 2000; 123: 7: 733-745.
22. Graham J.M., Grunewald R.A., Sogar H.J. Hallucinosis. J Neurol Neurosurg Psychiat 1967; 63: 5: 434-440.
23. Grossi D., Trojano L., Pellecchia M.T. Frontal dysfunction contributes to the genesis of hallucinations in non-demented Parkinsonian patients. Int J Geriat Psychiat 2005; 20: 7: 668-673.
24. Ito K., Nagano-Saito A., Kato T. et al. Striatal and extrastriatal dysfunction in Parkinson's disease with dementia: a 6-[18F]fluoro-L-dopa PET study. Brain 2002; 125: 6: 1358-1365.
25. Leroi I., Brandt J., Reich S. G. Randomized placebo-controlled trial of donepezil in cognitive impairment in Parkinson's disease. Int J Geriat Psychiat 2004; 19: 1: 1-8.
26. Mori T., Ikeda M., Fukuhara R. Correlation of visual hallucinations with occipital rCBF changes by donepezil in DLB. Neurology 2006; 66: 6: 935-937.
27. Okada K., Suyama N., Oguro H. et al. Medication-induced hallucination and cerebral blood flow in Parkinson's disease. J Neurol 1999; 246: 5: 365-368.
28. Parkinson J. An essay on the shaking palsy London: Sherwood Neely and Jones 1817; 66.
29. Perry E., Irving D., Kerwin J.M. et al. Cholinergic transmitter and neurotrophic activities in Lewy body dementia: similarity to Parkinson's and distinction from Alzheimer disease. Alzheitner Dis Assoc Disord 1993; 7: 2: 69-79.
30. Richard I.H., Justus A.W., Greig N.H. et al. Worsening of motor function and mood in a patient with Parkinson's disease after pharmacologie challenge with oral rivastigmine. Clin Neuropharmacol 2002; 25: 6: 296-299.
31. Rosler M. The efficacy of cholinesterase inhibitors in treating the behavioural symptoms of dementia. Int J Clin Pract 2002; 127: Supll 1: 20-36.
32. Saykin A.J., Wishart H.A., Rabin L.A. Cholinergic enhancement of frontal lobe activity in mild cognitive impairment. Brain 2004; 127: 7: 1574-1583.
33. Shaw W.S., Patterson T.L., Semple S.J. Longitudinal analysis of multiple indicators of health decline among spousal caregivers. Ann Behav Med 1997; 19: 2: 101-109.
34. Summeifield C., Gomez-Anson B., Tolosa E. et al. Dementia in Parkinson disease: a proton magnetic resonance spectroscopy study. Arch Neurol 2002; 59: 9: 1415-1420.
35. Sunderland T., Hill J.L., Mellow A.M. et al. Clock drawing in Alzheimer's disease: a novel measure of dementia severity. J Am Geriat Soc 1989; 37: 5: 725-729.
36. Tariot P.N., Solomon P.R., Morris J.C. et al. A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group Neurol 2000; 54: 12: 2269-2276.
37. Uc E.Y., Rizzo M., Anderson S.W. Visual dysfunction in Parkinson disease without dementia. Neurology 2005; 65: 12: 1907-1913.
38. th International Conference Alzheimer's and Parkinson's Disease 2003 Seville, Spain: 491.
39. Van Marum R.J., Jansen P.A. Increased risk of stroke during the use of olanzapine or risperidone in patients with dementia. Ned Tijdschr Geneeskd 2005; 149: 4: 165-167.
40. Woods S.P., Troster A.I. Prodromal frontal/executive dysfunction predicts incident dementia in Parkinson's disease. J Int Neuropsychol Soc 2003; 9: 1: 17-24.
41. Zarow C., Lyness S.A., Mortimer I.A., Chui H.C. Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer's and Parkinson's diseases. Arch Neurol 2003; 60: 3: 337-341.
42. Zhang L., Zhou F., Dani J.A. Cholinergic Drugs for Alzheimer's Disease Enhance in Vitro Dopamine Release. Mol Pharmacol 2004; 66: 3: 538-544.